Comment on "Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase"

Cancer Chemother Pharmacol. 2021 Nov;88(5):919-920. doi: 10.1007/s00280-021-04345-8. Epub 2021 Sep 1.

Author

Wing H Tong^{1

2}

Affiliations

¹ Department of Public Health and Primary Care (PHEG), Leiden University Medical Center (LUMC), Building 3, Hippocratespad 21, PO Box 9600, 2300 RC, Leiden, The Netherlands. w.h.tong@lumc.nl.
² Center for Specialized Geriatric Care, Argos Zorggroep "DrieMaasStede", Schiedam, The Netherlands. w.h.tong@lumc.nl.

PMID: 34468793
DOI: 10.1007/s00280-021-04345-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents* / therapeutic use
Asparaginase / therapeutic use
Asparagine / therapeutic use
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Antineoplastic Agents
Asparagine
Asparaginase